Quantum-Si outlines $103M operating expense target for 2025 while accelerating international expansion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2025
0mins
Source: SeekingAlpha
Management Insights: Quantum-Si's Q1 2025 earnings call highlighted a revenue increase of 84% year-over-year to $842,000, despite challenges in the U.S. academic market due to NIH funding uncertainties. The company is focusing on expanding its presence in the pharma and biotech sectors while maintaining a strong cash position expected to last into the second half of 2027.
Market Outlook and Risks: Analysts expressed concerns about ongoing market uncertainties affecting revenue growth, particularly in the U.S. academic sector, while management remains confident in their innovation roadmap and international expansion efforts. Key risks include NIH funding issues and potential impacts from tariffs, but management plans to adapt their strategy as needed.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QSI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QSI
Wall Street analysts forecast QSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QSI is 2.67 USD with a low forecast of 1.50 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.170
Low
1.50
Averages
2.67
High
4.00
Current: 1.170
Low
1.50
Averages
2.67
High
4.00
About QSI
Quantum-SI Incorporated is a life sciences company. The Company has designed and developed a hardware, consumable and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins. Its launched product consists of Platinum, the Platinum Analysis Software and consumables. Its flagship protein sequencing instrument, Platinum, is designed to make the power of single-molecule detection and NGPS accessible. Platinum is designed to provide a streamlined workflow compared to legacy MS workflows. Platinum uses its proprietary semiconductor chip that leverages time-domain sequencing with an initial focus on NGPS for an unbiased view of the proteome.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ark Invest Unveils 2026 Big Ideas, Forecasts 1.9% GDP Growth Boost
- Technological Acceleration: Ark Invest's report highlights that capital investment in disruptive innovation platforms could contribute 1.9 percentage points to annualized real GDP growth during this decade, emphasizing the potential of technologies like robotaxis and next-gen data centers.
- Strong ETF Performance: In 2025, Ark's Autonomous Technology & Robotics ETF and Space & Defense Innovation ETF achieved returns of 49.8% and 49.2%, respectively, showcasing the firm's ability to generate returns in emerging technology sectors.
- Bitcoin Holdings Surge: The report indicates that U.S. ETFs and public companies now hold 12% of total Bitcoin supply, with Bitcoin ETF balances up 19.7% and public company Bitcoin holdings up 73% in 2025, reflecting strong market demand for digital assets.
- Diverse Investment Opportunities: Ark Invest identifies several publicly traded companies, including Coinbase, Illumina, and Waymo, as key investment opportunities for the 2026 themes, indicating the firm's forward-looking approach to diversified investment strategies.
Continue Reading
Quantum-Si Grants 39,920 RSUs to New Employees Under 2023 Inducement Plan
- Employee Incentive Program: Quantum-Si has granted 39,920 restricted stock units (RSUs) to new employees under the 2023 Inducement Equity Incentive Plan, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in protein analysis.
- Vesting Conditions: The RSUs will vest 25% on December 20, 2026, with the remainder vesting in 12 equal quarterly installments, ensuring employees remain committed to the company, which promotes long-term retention.
- Compliance Assurance: This grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring Quantum-Si adheres to relevant regulations while attracting new employees, thus mitigating potential compliance risks.
- Strategic Implications: By implementing this incentive measure, Quantum-Si not only enhances employee loyalty but also accelerates innovation and market expansion in the proteomics field by attracting high-quality talent.
Continue Reading